Orphan Drugs and Rare Diseases 2015 returning to London in less than 2 weeks to review how big pharma is positioning itself in the emerging orphan drug industry

LONDON, UNITED KINGDOM, October 7, 2015 /EINPresswire.com/ -- Despite being used to treat approximately 1 out of every 1,000 patients’ worldwide, orphan drugs are now on the rise. The move towards specialty treatments is driving change across the industry because niche drugs are able to command a higher price, longer patent protection and fast track approval from the EMA.
(Source: The Sunday Times, Big pharma uses orphan drugs to cure financial headaches, 04.10.2015)

SMi Group is thrilled to announce: Orphan Drugs and Rare Diseases Conference returning to London in less than 2 weeks to review how big pharma is positioning itself in the emerging orphan drug industry. Discussions will revolve around both academic and big pharma perspectives on how to overcome the challenges of rare diseases.

David Boothe, Global Commercial Leader – GSK Rare Diseases, GSK will be give his presentation on: Meeting the challenges of rare diseases – a big pharma perspective, where he will be discussing creative development program design, and open and early engagement with regulators.

Furthermore, Dr Carlos R. Camozzi, Chief Medical Officer, Orphazyme will take the floor to discuss big pharma initiatives within the orphan drug industry. Hear his analysis of big pharma’s role in the emerging orphan drug industry, as well as the current and forward vision and what this means for the industry long term.

This two day networking event will review recent developments in the orphan drug and rare diseases industry and provide attendees with the opportunity to gain in-depth knowledge by: Learning key strategies and collaborations to accelerate rare disease clinical drug development; enhance knowledge on the role of patient organisations in promoting drug development for their disease.

Key speakers in 2015 include:
-Alastair Kent OBE, Director, Genetic Alliance UK & Chair of Rare Disease UK (RDUK)
-David Boothe, Global Commercial Leader - GSK Rare Diseases, GSK
-Dr Didier Caizergues, Head of regulatory Affairs Department, International Regulatory Affairs
department, GENETHON
-Dr Michael Skynner, Head of Rare Disease Alliances, Rare Disease Research Unit, Pfizer
-Stephane Demotz, Founder, DORPHAN S.A.
-Tim Miller, President & CEO, Abeona Therapeutics, and much more

Sponsored by: INC Research, Medical Research Network

The event programme also includes two interactive half-day post-conference workshops, entitled Market access to orphan drugs: Controversies, trends and solutions (Led by Colette Hamilton, Managing Director, ATP Market Access) and The rare disease patient perspective-from regulatory to clinical execution (Led by Christa van Kan, Team Lead Clinical Execution, PSR Orphan Experts, Steve Phinder, PhD Director, Envestia Ltd, and Nicolas Sireau, PhD, Chairman and CEO, AKU Society)

For more information or to register visit the website at www.orphandurgs-event.com
4th annual Orphan Drugs and Rare Diseases
19-20 October 2015
Holiday Inn Regents Park, London, UK
www.orphandurgs-event.com

------------------------- END --------------------------
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Anna Serazetdiova
SMi Group Ltd
+44 20 7827 6180
email us here